Market Closed -
Nasdaq
01:30:00 02/07/2024 am IST
|
5-day change
|
1st Jan Change
|
4.78
USD
|
+1.70%
|
|
+1.06%
|
+16.02%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11.09
|
48.54
|
73.55
|
43.85
|
87.2
|
164.2
|
-
|
-
|
Enterprise Value (EV)
1 |
11.09
|
48.54
|
73.55
|
43.85
|
87.2
|
164.2
|
164.2
|
164.2
|
P/E ratio
|
-0.27
x
|
-1.49
x
|
-1.91
x
|
-0.61
x
|
-2.75
x
|
-4.3
x
|
-5.02
x
|
-13.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
4.35
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
4.35
x
|
EV / EBITDA
|
-7,42,366
x
|
-
|
-22,39,330
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-0.73
x
|
-
|
-2.5
x
|
-
|
-
|
-4.94
x
|
-3.53
x
|
-6.36
x
|
FCF Yield
|
-138%
|
-
|
-40%
|
-
|
-
|
-20.2%
|
-28.4%
|
-15.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,047
|
5,993
|
9,454
|
17,897
|
21,166
|
34,341
|
-
|
-
|
Reference price
2 |
10.60
|
8.100
|
7.780
|
2.450
|
4.120
|
4.780
|
4.780
|
4.780
|
Announcement Date
|
13/03/20
|
11/03/21
|
10/03/22
|
16/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
37.72
|
EBITDA
|
-14.94
|
-
|
-32.84
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.53
|
-14.75
|
-33.09
|
-40.8
|
-27.25
|
-33.51
|
-38.54
|
-11.08
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-29.37%
|
Earnings before Tax (EBT)
1 |
-16.4
|
-14.73
|
-33.15
|
-42.35
|
-29.82
|
-34.51
|
-40.88
|
-11.5
|
Net income
1 |
-16.4
|
-14.73
|
-33.15
|
-42.35
|
-29.82
|
-34.44
|
-39.13
|
-11.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-30.5%
|
EPS
2 |
-39.80
|
-5.420
|
-4.080
|
-4.000
|
-1.500
|
-1.112
|
-0.9517
|
-0.3433
|
Free Cash Flow
1 |
-15.27
|
-
|
-29.44
|
-
|
-
|
-33.21
|
-46.56
|
-25.79
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-68.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/03/20
|
11/03/21
|
10/03/22
|
16/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.115
|
-7.226
|
-10.07
|
-12.64
|
-10.86
|
-8.578
|
-7.714
|
-6.572
|
-4.386
|
-5.982
|
-7.331
|
-9.47
|
-11.21
|
-11.83
|
-15.96
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.151
|
-7.573
|
-10.47
|
-13.08
|
-11.23
|
-8.992
|
-8.239
|
-7.108
|
-5.476
|
-6.494
|
-7.414
|
-9.943
|
-12.14
|
-12
|
-16.13
|
Net income
1 |
-7.151
|
-7.573
|
-10.47
|
-13.08
|
-11.23
|
-8.992
|
-8.239
|
-7.108
|
-5.476
|
-6.494
|
-7.588
|
-9.726
|
-11.46
|
-12
|
-16.13
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7600
|
-0.8000
|
-1.080
|
-1.350
|
-0.8300
|
-0.5000
|
-0.4300
|
-0.3400
|
-0.2600
|
-0.2600
|
-0.2433
|
-0.2867
|
-0.3100
|
-0.3150
|
-0.4250
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/22
|
12/05/22
|
11/08/22
|
14/11/22
|
16/03/23
|
09/05/23
|
14/08/23
|
09/11/23
|
28/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-15.3
|
-
|
-29.4
|
-
|
-
|
-33.2
|
-46.6
|
-25.8
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.05
|
-
|
-
|
-
|
-
|
0.26
|
0.31
|
0.38
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.01%
|
Announcement Date
|
13/03/20
|
11/03/21
|
10/03/22
|
16/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
4.78
USD Average target price
18
USD Spread / Average Target +276.57% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.02% | 164M | | +16.59% | 44.44B | | -9.89% | 37.99B | | +36.39% | 37.75B | | +27.12% | 30.78B | | -8.64% | 27.38B | | +11.81% | 26.17B | | +45.08% | 14.15B | | +32.85% | 12.59B | | -7.19% | 11.28B |
Other Biotechnology & Medical Research
|